The Metabolic Mechanism Underlying the Enhancing Effects of Glycine and Tryptophan on Kidney Function: How to Reduce EGFR Inhibitory Effect on AAs

Sania K. Elwia1*, Sahar M. Abo El Wafa2 and Yasmin M. Marei1
1-Department of Medical Biochemistry & Molecular Biology, Benha Faculty of Medicine, Benha University, Qalubia, Egypt
2-Forensic Medicine and Clinical Toxicology Department, Benha Faculty of Medicine, Benha University, Benha, Egypt
E-mail*: sanya.khairy@gmail.com - saharabouelwafa32@yahoo.com - jessy.marei@gmail.com

ARTICLE INFO
Article History
Received: 22/5/2021
Accepted: 11/7/2021

Keywords: N-acetylcysteine, glycine and tryptophan, EGFR, tryptophan hydroxylase, transforming growth factor β

ABSTRACT

Background: Chronic kidney disease (CKD) leads to a progressive decline in kidney function that eventually progresses to end-stage renal disease. It is critical to identify people at risk for renal disease and to intervene early to avoid kidney damage. Tryptophan hydroxylase (TPH-1) is an accurate biomarker for CKD early stage. The loss of tryptophan hydroxylase contributes to kidney injury. N-acetylcysteine, glycine, and tryptophan can arrest renal fibrosis development and progression through the anti-fibrotic effect of tryptophan hydroxylase and the protective effect of N-acetylcysteine.

Objectives: This study aims to assess the metabolic effect of N-acetyl-l-cysteine on kidney function as an EGFR inhibitor and its effect on AAs depletion. In addition, to evaluate the effect of glycine and tryptophan on kidney injury and renal fibrosis progression.

Results: Eight weeks of administration of pemetrexed led to a significant increase in serum, urea, creatinine, and uric acid. Administration of N-acetylcysteine (NAC with pemetrexed) resulted in a significant decrease in biochemical kidney function. Also, glycine and tryptophan directly affect renal function; increased expression of tryptophan hydroxylase with decrease expression of EGFR and transforming growth β (TGF-β), compared to N-acetylcysteine group.

Conclusion: N-acetylcysteine, glycine, and tryptophan can halt the depletion of AAs in the presence of urea and EGFR. Glycine and tryptophan both have a direct effect on renal function due to their uric acid-lowering properties.

INTRODUCTION

The increasing chronic kidney disease (CKD) prevalence threatens the health and overall quality of life. The biomarkers of the pathogenesis of CKD and the associated complications are essential for CKD diagnosis and treatment (Yiming Hao et al., 2020). Pemetrexed is a methotrexate derivative. It is authorized for advanced non-small cell lung cancer and pleural mesothelioma treatment. Pemetrexed may result in a decrease in
creatinine clearance, AKI, and other types of renal impairment, which may lead to irreversible CKD (Stavroulopoulos, A. et al., 2010).

After kidney damage, the loss of functioning nephrons stimulates compensatory development of the remaining ones, allowing functional adaptability. These compensatory processes, however, activate signaling pathways, resulting in pathological changes and chronic kidney disease (Mohamad Zaidan et al., 2020).

In cell signaling, tyrosine kinases play a critical role. Dysregulation of their activity can lead to fibrotic disorders. Thus, pathogenic tyrosine kinase activation can promote fibrogenesis (Overstreet, J. M. et al., 2017). In renal tissue, the epidermal growth factor receptor (EGFR) is expressed, primarily in the distal and collecting tubules epithelial cells, peritubular vessels, and glomeruli, with increased expression in affected kidneys, compared to normal kidneys (Skibba, M. et al., 2016) (Yang, L. et al., 2019). Because activation of these receptors has been linked to a variety of forms of chronic kidney disease, inhibiting target EGFR by interfering with its signaling pathway has been shown to have a protective impact against renal fibrosis.

A method for managing individuals with chronic renal disease is to use angiotensin-converting enzyme inhibitors (ACEI) to block the renin-angiotensin-aldosterone pathway. Currently, there is no effective treatment that can halt chronic renal disease development. In individuals with chronic kidney disease, antioxidants such as N-acetylcysteine (NAC) have been described as potential treatments and surrogate biomarkers for tubular damage or renal fibrosis. (Marcin Renke et al., 2009).

Tryptophan hydroxylase is an accurate metabolic biomarker of early-stage kidney disease. TPH-1 deficiency exacerbates renal damage by activating NF-κB and suppressing Nrf2 signaling pathways. As a result, targeting TPH-1 may provide a novel method for the treatment of chronic kidney disease. (Dan-Qian Chen et al., 2019). Alterations in tryptophan act as a chemical fingerprint and can be utilized as biomarkers for detecting or monitoring biological processes (Kosmides A.K. et al., 2013) (Holmes E. et al., 2008).

MATERIALS AND METHODS

Animal Preparation:

Thirty-two male Sprague-Dawley rats (10–12 weeks of age, 250–300 g) were utilized in this study. They were purchased from Helwan Experimental Animal Breeding Farm. The Laboratory Animal Care and Use Committee approved all protocols. The experimental rats were kept in a room with a temperature of 25 ±1° C with a 12-hour light/dark cycle and provided regular laboratory food and water. To minimize the possibility of our results being influenced by the sex hormones variation during the menstrual cycle in female rats, only male rats were utilized.

Animal Treatment:

Rats were randomly categorized into four groups (eight per group). Group 1 received pemetrexed. Each rat was injected with ALIMTA (IV, 10 mg/kg), a sterile white-to-light yellow or green-yellow lyophilized powder, for 8 weeks. Group 2 received N-acetylcysteine (IP, 80 mg/kg) 30 minutes before pemetrexed for five weeks. Group 3 received Glycine (6 g) and L-Tryptophan (0.4 g) 30 minutes before pemetrexed for eight weeks. Group 4 was a control group, received normal saline by gavage.

Drugs:

N-acetylcysteine (NAC), glycine, and tryptophan were supplied from Sigma-Aldrich Chemical Co. (St Louis, Missouri, USA). Before use, all drugs were dissolved in distilled water and were freshly prepared. After eight weeks, animals were anesthetized with isoflurane and underwent cardiac puncture for blood collection. To evaluate renal function,
blood creatinine, urea, and uric acid were quantified using colorimetric assays in a clinical laboratory utilizing an automated biochemical analyzer (Pointe Scientific, Canton, MI, or Sigma kits).

**RNA Extraction, Reverse Transcription, Quantitative Analysis of Transcripts Using qRT-PCR:**

RNA was isolated from serum according to the manufacturer's instructions using a RNeasy kit (Qiagen). Nanodrop analysis was used to assess RNA quality and amount. Reverse transcription was done at 25°C, 42°C, and 70°C for 10 min, 1 h, and 10 min, respectively. qRT-PCR was performed using 1 µl of cDNA (50 ng), 5 µl of SYBR Green/0.2 µl of ROX qPCR Master Mix (2X, Fermentas, Germany), and 1 µl of forward and reverse primers adjusted to a total volume of 10 ml using nuclease-free water. GAPDH was used as a reference gene.

Relative quantification of EGFR, TPH1, and TGF was performed with the 2^{ΔΔCt} method and analyzed by ABI prism 7500. The Boxplot software and values were normalized to the quantity of GAPDH.

**Table 1:** primers sequences of EGFR, TGF, TPH1 and GAPDH.

|            | Forward Sequence | Reverse Sequence |
|------------|------------------|------------------|
| EGFR       | GAGGGACCCTGCTTGGT- | AACACGCACTATGTAAGA- |
| TGF beta   | TACCTGAACCGTGTTCCTC | GGGTCTGAGGTATCGCCAGGA |
| Trytophan hydroxylase | TCTGTCCTGAACCGTGTGTCCTGT | ACGGTAGACATTGGCTTTGAAGCC |
| GAPDH      | CAGTGCCAGCTGCCTTCAT | AGGGCCATCCACAGTCTTC |

**Statistical Methods:**

SPSS software version 25 was used for statistical analysis (IBM, Armonk, New York, United States). Quantitative data were presented as means and standard deviations or medians and IQRs. Comparisons between the study groups were done using one-way ANOVA or Kruskal-Wallis test. Post-hoc analyses were done using Bonferroni’s method. All statistical tests were two-sided. P values less than 0.05 were considered significant.

**RESULTS**

Creatinine showed an overall significant difference (P-value <0.001) between groups. Pairwise analysis revealed that group I had higher creatinine than groups II, III, and IV. Also, group II showed higher creatinine compared to groups III & IV. No significant difference was observed between groups II & IV (Table 2 & Fig. 1).

**Table 2** Creatinine in the studied groups

|            | Group I | Group II | Group III | Group IV | P-value |
|------------|---------|----------|-----------|----------|---------|
| Creatinine | 3.49 ±0.49 | 1.8 ±0.19 | 1.33 ±0.29 | 1.07 ±0.12 | <0.001 |
| Post-hoc   | 2, 3, 4 | 1, 3, 4 | 1, 2 | 1, 2 | |

Data was presented as mean ±SD. One-way ANOVA was used. All post hoc comparisons were Bonferroni adjusted 1; sig. diff. from G I 2; sig. diff. from G II 3; sig. diff. from G III 4; sig. diff. from G IV
Urea showed an overall significant difference (P-value <0.001) between groups. Pairwise analysis revealed that group I had higher urea than groups II, III, and IV. Also, group II showed higher urea compared to groups III & IV. No significant difference was observed between groups II & IV (Table 3 & Fig. 2).

Table 3: Urea in the studied groups

|        | Group I | Group II | Group III | Group IV | P-value |
|--------|---------|----------|-----------|----------|---------|
| Urea   | 94 ±12  | 56 ±4    | 41 ±5     | 38 ±2    | <0.001  |
| Post-hoc| 2,3,4   | 1,3,4    | 1,2       | 1,2      |         |

Data was presented as mean ±SD. One-way ANOVA was used. All post hoc comparisons were Bonferroni adjusted

1; sig. diff from G I      2; sig. diff from G II      3; sig. diff from G III      4; sig. diff from G IV

Uric acid showed an overall significant difference (P-value <0.001) between groups. Pairwise analysis revealed that group I had higher uric acid than groups II, III, and IV. Also, group II showed higher uric acid compared to groups III & IV. Moreover, group II was significantly higher compared to group IV (Table 4).
Table 4: Uric acid in the studied groups

|                  | Group I  | Group II | Group III | Group IV | P-value |
|------------------|----------|----------|-----------|----------|---------|
| Uric acid        | 6.7 ±0.6 | 4.4 ±0.7 | 3.5 ±0.2  | 1 ±0.2   | <0.001  |
| Post-hoc         | 2,3,4    | 1,3,4    | 1,2,4     | 1,2,3    |         |

Data was presented as mean ±SD. One-way ANOVA was used. All post hoc comparisons were Bonferroni adjusted.

1; sig. diff. from G I  2; sig. diff. from G II  3; sig. diff. from G III  4; sig. diff. from G IV

TGF gene showed an overall significant difference (P-value <0.001) between groups. Pairwise analysis revealed group I had significantly higher TGF than groups III, IV. There were no other significant differences between groups (Table 5).

Table 5: TGF gene in the studied groups

|                  | Group I  | Group II | Group III | Group IV | P-value |
|------------------|----------|----------|-----------|----------|---------|
| TGF gene         | 5.099    | 1.2285   | 1.2245    | 0.194    | <0.001  |
|                  | (4.787 - 5.495) | (1.033 - 2.359) | (0.589 - 1.49) | (0.181 - 0.389) |     |
| Post-hoc         | 3,4      | -        | 1         | 1        |         |

Data were presented as median (IQR). Kruskal-Wallis test was used. All post hoc comparisons were Bonferroni adjusted.

1; sig. diff. from G I  2; sig. diff. from G II  3; sig. diff. from G III  4; sig. diff. from G IV

Epidermal growth factor receptor (EGFR) showed an overall significant difference (P-value <0.001) between groups. Pairwise analysis revealed that group I had significantly higher EGFR than groups III, IV. Also, group II had higher EGFR than group IV. There were no other significant differences between groups (Table 6 & Fig. 3).

Table 6: EGFR in the studied groups

|                  | Group I  | Group II | Group III | Group IV | P-value |
|------------------|----------|----------|-----------|----------|---------|
| EGFR             | 5.23     | 2.164    | 1.581     | 0.176    | <0.001  |
|                  | (4.452 - 5.981) | (1.59 - 3.521) | (1.179 - 2.169) | (0.166 - 0.71) |     |
| Post-hoc         | 3,4      | 4        | 1         | 1        |         |

Data were presented as median (IQR). Kruskal-Wallis test was used. All post hoc comparisons were Bonferroni adjusted.

1; sig. diff. from G I  2; sig. diff. from G II  3; sig. diff. from G III  4; sig. diff. from G IV

EGFR; Epidermal growth factor receptor.

Fig.3: EGFR in different study groups
Tryptophan hydroxylase-1 (TPH-1) showed an overall significant difference (P-value <0.001) between groups. Pairwise analysis revealed that group I had significantly lower TPH than groups II, III, and IV. There were no other significant differences between groups (Table 7 & Fig. 4).

Table (7) TPH-1 in the studied groups

|       | Group I       | Group II      | Group III     | Group IV      | P-value |
|-------|---------------|---------------|---------------|---------------|---------|
| TPH-1 | 0.168 (0.164 - 0.477) | 3.953 (3.234 - 4.709) | 4.233 (3.444 - 4.717) | 5.453 (4.969 - 6.239) | <0.001  |

Data were presented as median (IQR). Kruskal-Wallis test was used. All post hoc comparisons were Bonferroni adjusted

1; sig. diff. from G I    2; sig. diff. from G II    3; sig. diff. from G III    4; sig. diff. from TPH-1; Tryptophan hydroxylase-1

Fig.4: TPH-1 in different study groups

**DISCUSSION**

Chronic kidney disease (CKD) is a prominent cause of noncommunicable disease morbidity and death, affecting 10% of the world population, chronic kidney disease (CKD) is the main cause of cardiovascular illness, early death, and end-stage renal disease. As a result, avoiding the development of CKD is critical (Jha V et al., 2013).

N-acetylcysteine (NAC) is a glutathione regenerator. NAC has been studied and is now being utilized to help avoid iatrogenic acute kidney damage and help reduce chronic kidney disease progress (Johnny W. et al., 2021).

According to the current study, N-acetyl cysteine with pemetrexed showed a significant decline (P < 0.001) in serum creatinine, urea, uric acid, TGF-β1, and epidermal growth factor receptor (EGFR), and an increase in TPH expression, compared to the pemetrexed group.

Prior studies evaluated tyrosine kinase inhibitors effect on N-acetyl glutamate synthase, which is a urea cycle key enzyme (Li, J. et al., 2019) (Pham-Danis C. et al., 2019). The current study showed that pemetrexed might interfere with glutamate incorporation in ERK1/2 stimulatory signals by halting glutamate receptors activation by Src tyrosine kinases, which may direct glutamate towards the elevation of urea formation in the blood.
Pemetrexed blocks thymidylate synthase (TS), decreasing the available thymidine for DNA synthesis. Additionally, pemetrexed inhibits dihydrofolate reductase (DHFR) and glycaminide ribonucleotide formyltransferase (GARFT), two enzymes important for the de novo production of thymidine and purine nucleotides. After entering the cell via the reduced folate carrier, pemetrexed is polyglutamated. Glutamation increases pemetrexed cellular retention and intracellular half-life while simultaneously increasing the inhibitory activity of the polyglutamated metabolites by more than 60-fold (Paz-Ares L. et al., 2003). Thus, an increase in uric acid levels may develop as a result of excessive nucleic acid breakdown from dead cells following a high dosage of the medication (Pui C.H. et al., 1997).

N-acetyl-l-cysteine use as an EGFR inhibitor prevented the AAs depletion caused by urea. This finding shows the inhibitory effect of urea over the EGF/EGFR system (Rasoul Kowsar et al., 2020). Urea signaling is sensitive to NAC supplementation (Zhao H. et al., 2003).

After eight weeks of continuous ingestion of combined glycine and tryptophan with pemetrexed, serum uric acid significantly decreased, renal function improved, expression of TGF-β1 decreased, and the expression of TPH-1 increased, according to the current study. The combination of glycine and tryptophan has a uric acid-lowering effect, which influences renal function and significantly suppresses the elevation in uric acid levels.

Afferent arteriopathy, inflammation, and stimulation of the renin-angiotensin system are all possible processes underlying kidney injury induced by uric acid buildup. The consequences of high uric acid are believed to be produced by uric acid's direct toxicity to the kidney (Kang DH, Chen W, 2011). Shunji Oshima et al. (2021) are in line with our results.

The excretion of urates into the urine leads to decreased serum uric acid concentration (Oshima S. et al,.2019). The AA may impair renal function; a single combination dosage of glycine and tryptophan transiently improves eGFR, indicating that eGFR, as a measure of renal function, may be increased via continuous supplementation with combined glycine and tryptophan. Glycine is metabolized to produce various compounds, including glutathione, nucleic acid bases, heme, creatine, and bile. The conversion of glycine to creatinine via creatine may affect the blood creatinine level.

The EGFR may impede the transfer of AAs in the pemetrexed group. It is suggested that the greater depletion of AAs in renal injury is due to urea inhibitory effect on the EGF/EGFR pathway. (Garofalo, A. et al., 2010) (Amaral D. N. et al., 2019) (Jiang N. et al., 2016).

Urea effects on AAs via the EGFR system were investigated using NAC. It has been demonstrated that NAC inhibits EGFR activation. NAC is a sensitive regulator of urea signaling (Zhao et al., 2003).

The potential relation between altered levels of epidermal growth factor and elevated uric acid with reduced eGFR might be important in preventing, diagnosing, and managing impaired kidney function (Wu J. et al., 2018).

TGF-1 is a fibrogenic cytokine that may promote the synthesis of ECM, change its breakdown, and is implicated in the primary pathogenic processes of chronic kidney disease. The stimulation of the EGFR signaling pathway was essential for boosting TGF-1 production. (Chen et al.,2011) demonstrated that inhibiting EGFR can reduce TGF-β1 /2/p38 expression (Lu T. C. et. al., 2009) (N Liu et al., 2012). The EGFR inhibitor can slow the course of kidney damage and fibrosis in the kidney. This impact might be mediated at least by an antioxidant effect, which targets the STAT3 activation pathway, the ERK1/2 pathway, and the profibrogenic marker TGF-1. NAC treatment can delay the progression of fibrosis (Chen et al., 2011).

Renal fibrosis is caused by the interaction of cellular and molecular processes triggered by glomerular damage and involving podocytes and numerous pro-fibrotic agents (Tiago Giuliani Lopes et al., 2019).
Connective tissue growth factor (CTGF) functions as a mediator of TGF-β activity on mesenchymal cells. Both are co-expressed in various kinds of glomerular damage (Ito et al., 2010). Multiple processes contribute to renal fibrosis, including cellular events (monocyte and T cell infiltration), the activity of critical signaling molecules (NF-B, TGF-/Smad), cell death, and an excess of matrix-degrading enzymes (Liu Y. 2006).

For six weeks, a powder combination of glycine and tryptophan (3g and 0.2g, respectively) was eaten at bedtime once daily, and serum uric acid levels were considerably reduced (Oshima S et al., 2019). Up to 90 g glycine or 5.0 g L-tryptophan per day was consumed without severe adverse effects (Pérez-Torres et al., 2017) (Hiratsuka C et al., 2013). The combination of two AA is safe, considering that they were continually ingested for six weeks with no change in physiological parameters (Ter Wee PM et al., 1986).

TPH-1 deficiency promotes kidney damage and fibrosis via activating NF-B and blocking Nrf2 pathways. Thus, we propose that activation of TPH-1 be used as a target in the therapy of chronic kidney disease.

TPH-1 expression was decreased following TGF-β1 and LPS-induced kidney damage. TPH-1 deficiency decreased epithelial cell marker expression and elevated pro-fibrotic marker expression, resulting in extracellular matrix buildup and kidney fibrosis (Wang, Y. F. et al., 2016).

Wei Q et al., 2014 revealed the role of tryptophan and amino acids as potential biomarkers and their biologically significant role, both within normal renal homeostasis and diseased kidney. Additionally, glycine at dosages up to 90 g per day for several weeks shows no significant side effects (Pérez-Torres I et al., 2017) (Friedman M., 1947).

Glycine increased uric acid excretion and urate clearance. Continuous glycine and tryptophan feeding resulted in a rise in urine pH (Glycine acts as a buffer and is thus utilized as an antacid). Uric acid solubility in water increases as pH levels increase, and uric acid excretion is greater in alkaline urine than in acidic urine. Elevated urine pH caused by glycine and tryptophan increases uric acid solubility, thereby increasing urinary uric acid excretion (Kanbara A. et al., 2012).

**CONCLUSION**

Early detection and precise monitoring of chronic kidney disease (CKD) can enhance care and delay development to end-stage renal disease. Depletion or appearance of AAs (tryptophan) could change in the presence of urea and EGFR.

**List of Abbreviations**

chronic kidney disease (CKD)
N-acetyl-l-cysteine NAC
Tryptophan hydroxylase (TPH-1)
Transforming growth factor β (TGF-β)
Acute Kidney injury AKI
ANGIOTENSIN-converting enzyme inhibitors (ACEI)
nuclear factor-kB
nuclear factor erythroid 2-related factor 2 Nrf2
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; EGFR, epidermal growth factor receptor
Thymidylate synthase (TS)
Dihydrofolate reductase (DHFR)
Glycinamid ribonucleotide formyltransferase (GARFT), Connective tissue growth factor (CTGF)
5-MTP 5-methoxytryptophan
LPS lipopolysaccharide
eGFR estimated glomerular filtration rate
AA amino acid

**Conflicts of Interest/Competing interests no conflict**

**Ethics Approval**

* Consent to Participate (Ethics) not applicable
* Consent to Publish (Ethics) -not applicable
* Authors’ contributions -no contribution

**Availability of data and material** from molecular biology and biotechnology unit at Faculty of Medicine, Banha University

**REFERENCES**

Anne Fraticelli, Bénédicte Devictor, Pierre Julien Bouvenot, Nicolas Coltel, Gérald Lamarche, Philippe Astoul, (2009): Intrapleural Administration of Pemetrexed: A Pharmacokinetic Study in an Animal Model. *Journal of Thoracic Oncology*, 4, (3)404–408.

Boudonck KJ, Mitchell MW, Ne´met L, Keresztes L, Nyska A, Shinar D (2009): Discovery of metabolomics biomarkers for early detection of nephrotoxicity. *Toxicology Pathology*, 37(3):280–92.

Chen S.C., Guh J.Y., Lin T.D., Chiou S.J., Hwang C.C., Ko Y.M., Chuang L.Y. (2011): Gefitinib attenuates transforming growth factor-beta1-activated mitogen-activated protein kinases and mitogenesis in NRK-49F cells. *Translation Research*, 158, 214–224.

Chesney R.W., Han X., Patters A.B. (2010) Taurine and the renal system. *Journal of Biomedical Science* 17: S4.

Christman A.A., Mosier E.C (1929): Purine metabolism. II. The effect of the ingestion of glycine on the excretion of endogenous uric acid., *Journal of Biological Chemistry*, 83:11–19.

Dan-Qian Chen, Gang Cao, Hua Chen, Christos P. Argyopoulos, Hui Yu, Wei Su, Lin Chen1, David C. Samuels, Shougang Zhuang, George P. Bayliss8, Shilin Zhao5, Xiao-Yong Yu, Nosratola D. Vaziri, Ming Wang1, Dan Liu1, Jia-Rong Mao9, Shi-Xing Ma, Jin Zhao11, Yuan Zhang11, You-Quan Shang4, Huining Kang3, Fei Ye5, Xiao-Hong Cheng9, Xiang-Ri Li1, Li Zhang11, Mei-Xia Meng, Yan Guo & Ying-Yong Zhao | (2019) : Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. *Nature Communications*, 10:1476.

do Amaral, D. N. Fokoue H., Bastos da Silva E.M., Sant’Anna, C.M. Daniel Rauh, Eliezer J. Barreiro, Stefan Lauffer & Moreira Lim L(2019) : A novel scaffold for EGFR inhibition: introducing N-(3-(3-phenylureido) quinoxalin-6-yl) acrylamide derivatives. *Science. Report*, 9(1):14.

Evangéline Pillebout, Jonathan B. Weitzman, Martine Burtin, Carla Martino, Pierre Federici, Moshe Yaniv, Gérard Friedlander and Fabiola Terzi, JUnD (2003) protects against chronic kidney disease by regulating paracrine mitogens. *American Journal of Clinical Investigation*. 15; 112(6): 843–852.

Friedman M. (1947): The effect of glycine on the production and excretion of uric acid. *Journal of Clinical Investigation*. 26:815–819.
Garofalo, A., Goossens L., Lemoine A., Farce A., Arlot Y., Depreux P. (2010): Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer. *Journal of Enzyme Inhibition. Medical Chemistry*, 25, 158–171

Hiratsuka C., Fukuwatari T., Sano M., Saito K., Sasaki S., Shibata K. (2013): Supplementing healthy women with up to 5.0 g/d of L-tryptophan has no adverse effects. *The Journal of Nutrition*, 143: 859-866

Hocher B., Adamski J. (2017). Metabolomics for clinical use and research in chronic kidney disease. *Nature Review Nephrology*, 13(5):269–84.

Holmes E., Wilson I.D., Nicholson J.K. (2008): Metabolic phenotyping in health and disease. *Cell*, 134 (5):714–717

Hostetter T.H., Olson J.L., Rennke H.G., Venkatachalam M.A., Brenner B.M. (1981): Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. *American Journal of Physiology*, 241(1): F85–F93

Jha V., Garcia-Garcia G., Iseki K., Li Z., Naicker S., Plattne B. (2013): chronic kidney disease: global dimension and perspectives. *Lancet*, 382: 260-272

Jiang N., Bu Y., Wang Y. Nie M. Zhang D. and Zhai X. (2016): Design, synthesis and structure-activity relationships of novel diaryl urea derivatives as potential EGFR inhibitors. *Molecules*, 21(11): 1572.

JohnnyW-Brianna LH., Owen J. Jennifer Kong C., Clark E, Benjamin J.W. Shabana C., Hiremath S. (2021): A Systematic Review of the Effect of N-Acetylcysteine on Serum Creatinine and Cystatin C Measurements Kidney. *International Reports*, 6, (2): 396-403

Kanbara A., Miura Y., Hyogo H., Chayama K., Seyama I (2012): Effect of urine pH changed by dietary intervention on uric acid clearance mechanism of pH-dependent excretion of urinary uric acid. *Nutrition Journal*, -2891-11-39.

Kang DH, Chen W (2011): Uric acid and chronic kidney disease: new understanding of an old problem. *Seminars in Nephrology*, 31: 447-452

Kosmides A.K., Kamisoglu K., Calvano S.E., Corbett S.A., Androulakis I.P. (2013): Metabolomic fingerprinting: challenges and opportunities. Critical Review Biomedical England. 41(3):205–221.

Laurent Greillier Suzanne Mojanel, Anne Fraticelli Bénédicte Devictor, Pierre Pharm, Julien Bouvenot MDP Nicolas Coltel H Gérald Lamarche Philippe Astoul (2009): Intrapleural Administration of Pemetrexed: A Pharmacokinetic Study in an Animal Model. *Journal of Thoracic Oncology*, 4 (3), 404-408.

Li, J., Halfter, K. Zhang, M. Saad, C. Xu, K. Bauer, B. Huang, Y. Shi L. & Mansmann U.R. (2019): Computational analysis of receptor tyrosine kinase inhibitors and cancer metabolism: implications for treatment and discovery of potential therapeutic signatures. *BMC Cancer*, 19, 600.

Liu Y. (2006): Renal fibrosis, new insights into the pathogenesis and therapeutics. Kidney International.; 69: 213–217.

Liu, N., Kan Guo, J. Pang, M, Tolbert E, I Ponnusamy M, Gong R Bayliss G Lane D Dworkin, Yan H Zhuang S; (2012). Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis. J. Am. Soc. Nephrol. 23, 854–867.

Lu, T. C., Wang ZH, Xiaobei Feng, Chuang, PY Wei Fang, Yuhong Shen, David E Levy, Huabao Xiong, Nan Chen, He JC (2009): Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. *Kidney International*, 76, 63–71

Marcin Renke Leszek Tylicki Przemyslaw Rutkowski (2009): The Effect of N-Acetylcysteine on Proteinuria and Markers of Tubular Injury in Non-Diabetic Patients with Chronic Kidney Disease. *Kidney*, 31(6):404-
Mohamad Zaidan, Martine Burtin, Jitao David Zhang, Thomas Blanc, Pauline Barre, Serge Garbay, Clément Nguyen, Florence Vasseur, Lucie Yannine, Serena Germano, Laura Badi, Marie-Claire Gubler, Morgan Gallazzini, Gérard Friedlander, Marco Pontoglio, and Fabiola Terzi. (2020): Signaling pathways predisposing to chronic kidney disease progression. *American Journal of Clinical Investigation, 7; 5(9): e126183.*

Niewczas M.A., Sirich T.L., Mathew A.V., Skupien J., Mohney R.P., Warram J.H. (2014): Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. *Kidney International, 85(5):1214–24.*

Oshima S., Shiiya S., Nakamura Y. (2019): Combined supplementation with glycine and tryptophan reduces purine-induced serum uric acid elevation by accelerating urinary uric acid excretion: A randomized, single-blind, placebo-controlled, crossover study. *Nutrients, (11)11: 2562.*

Oshima S., Shiiya S., Nakamura Y. (2019): Serum uric acid-lowering effects of combined glycine and tryptophan treatments in subjects with mild hyperuricemia: A randomized, double-blind, placebo-controlled, crossover study. *Nutrients, 11: 564.*

Overstreet, J. M. Yinquiet Wang, Xin Wang, Aolei Niu, Leslie S. Gewin, Bing Yao, Raymond C., Zhi Zhang HM(2017): Selective activation of epidermal growth factor receptor in renal proximal tubule induces tubulointerstitial fibrosis. Federtion American Societies. Experimental Biology Journal, 31, 4407–4421.

Paz-Ares L, Bezares S, Tabernero J,(2003). Review of a promising new agent - pemetrexed disodium. *Cancer,97 8:2056-2063.*

Pérez-Torres I., Zuniga-Munoz A.M., Guarner-Lans V. (2017): Beneficial effects of the amino acid glycine. *Mini-Reviews in Medicinal Chemistry, 17: 15–32.*

Pham-Danis, C., Sarah Gehrke, Etienne Danis, Andrii I. Rozhok, Daniels M.W., Dexiang Gao, Christina Collins I, Di Paola J.T., D'Alessandro A. DeGregori J.(2019): Urea cycle sustains cellular energetics upon EGFR inhibition in EGFR-mutant NSCLC.Molecular. *Cancer Resarch, 17, 1351–1364.*

Pui C.H., Relling M. V., Lascombes F., Harrison P. L., Struxiano A., Mondesir J. M., Ribeiro R. C., Sandlund J. T., Rivera G. K., Evans W. E., Mahmoud H. H. (1997): Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia, 1813:-1816.

Rasoul Kowsar,Alireza Mansouri , Nima Sadeghi , Mohammad HeidaranAliAbadi , Seyed Mehdighoreishi , Khaled Sadeghi1 & Akio Miyamoto (2020): multilevel analysis identifie the diferent relationships between amino acids and the competence of oocytes matured individually or in groups .*Scientific Reports, 10:16082]*

Reeds, P.J.; Mersmann, H.J(1991) Protein and energy requirements of animals treated with β-adrenergic agonists: A discussion,. *Journal of Animal Science, 69, 1532–1550.*

Sharma K., Karl B., Mathew A.V., Gangoiti J.A., Wassel C.L., Saito R., (2013): Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. *Journal of American Societies Nephrology; 24(11):1901–12.*

Shunjı Oshima, Sachie Shiiya, Yasunori (2021): Enhancing effect of glycine and tryptophan mixture on estimated glomerular filtration rate in healthy participants: A randomized, double-blind placebo-controlled parallel study. *Functional Foods in Health and Disease; 11(1): 24-33.*

Silva R. E, Baldim J.L., Chagas-Paula D.A., Soares M.G., Lago J.H.G., Gonc¸alves R.V. (2018): Predictive metabolomic signatures of end-stage renal disease: A multivariate analysis of population-based data. *Société Française de Biochimie et Biologie Moléculaire, 152:14–30.*
Sis, B., Sarioglu S., Celik A., Zeybel M., Soylu A., Bora S. (2004) : Epidermal growth factor receptor expression in human renal allograft biopsies: an immunohistochemical study. *Translation. Immunology*, 13, 229–232

Skibba, M., Qian Y., Bao Lan J. Peng K., Zhao Y., Zhong P., Hu J., Li X., Liang G. (2016) : New EGFR inhibitor, , prevents renal fibrosis in angiotensin II-stimulated mice. *Europan. Journal of Pharmacology*, 789, 421–430.

Yang, L., Yuan, H. Yu Y., Yu N., Ling L., Niu J., Gu J (2019) : Epidermal growth factor receptor mimotope alleviates renal fibrosis in murine unilateral ureteral obstruction model. *Clinical Immunology*, 205, 57–64

Stavroulopoulos A., Nakopoulou L., Xydakis A., i Aresti V., Aggeliki Nikolakopoulou A., Klouvas G. (2010) : Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed. *Renal failure*; 32(8):1000-1004.

Ter Wee P.M., Rosman J.B., Van Der Geest S., Sluiter W.J., Donker A.J. (1986): Renal hemodynamics during separate and combined infusion of amino acids and dopamine. *Kidney International*, 29: 870-874.

Tiago Giuliani Lopes, Maysa Lucena de Souza, Vinicius Duval da Silva ID , Mariane dos Santos, William Israel Cardoso da Silva , Thiago Pereira Itaquy, Henrique Iahnke Garbin, Francisco Veri’sismo Veronese (2019) : markers of renal fibrosis: How do they correlate with podocyte damage in glomerular diseases? ). *PLOS ONE*, 14(6): e0217585

Wang, Y. F., Hsu Y.I., Wu H.F., Lin Lee G., Yang J.Y., Yet SF, Kenneth K. Wu, Kuo C.C. (2016) : Endothelium-derived 5-methoxytryptophan is a circulating anti-inflammatory molecule that blocks systemic inflammation. *Journal of scientific report*, 119, 222–236

Wei Q., Xiao X., Fogle P., Dong Z. (2014): Changes in metabolic profiles during acute kidney injury and recovery following ischemia/reperfusion. *PLoS One*, 9(9): e106647.

Wu, J. Jia J., Li Z. Pan, HWang, A Guo X., Wu S Zhao X(2018) : Association of estimated glomerular filtration rate and proteinuria with all-cause mortality in community-based population in China: A Result from Kailuan Study. *Scientific Report*, 8, 2157-2055

Yang, L., Yuan H., Yu Y., Yu N., Ling L., Niu J., Gu Y. (2019): Epidermal growth factor receptor mimotope alleviates renal fibrosis in murine unilateral ureteral obstruction model. *Clinical Immunology*, 205, 57–64

Yiming Hao, Luis Tanon Reyes, Robert Morris, Yifeng Xu1, YiqinWang & Feng Cheng (2020): changes of protein levels in human urine reflect the dysregulation of signaling pathways of chronic kidney disease and its complications. *Scientific Reports*, 10:20743

Zhao, H., Tian, W., Xu, H. & Cohen, D. M. (2003) : Urea signalling to immediate-early gene transcription in renal medullary cells requires transactivation of the epidermal growth factor receptor. *Biochemistry Journal*, 370, 479–487